Skip to content
type1.science
Phase 3RecruitingNCT07222332

BARICADE-PRESERVE: Baricitinib in newly diagnosed T1D

Phase-3 trial testing baricitinib in children and adults newly diagnosed with stage-3 T1D, following the positive BANDIT phase-2 result.

Primary endpoints

  • Change in C-peptide AUC at 52 weeks

Results so far

No results posted. Live-checked 27 August 2026 (ClinicalTrials.gov last update 21 August 2026): still recruiting; estimated n=300; estimated primary completion July 2028.

The full picture

BARICADE-PRESERVE is the phase-3 confirmation test for baricitinib's new-onset beta-cell-preservation signal.